ClinicalTrials.gg
Not yet recruitingNCT07108985Updated Aug 7, 2025

Effect of Add-on SGLT2i, TZD, or Combination Therapy in Type 2 Diabetes Patients on DPP4 Inhibitors

A Phase 4 interventional study of Sitagliptin 100 mg and Sitagliptin 100 mg + Dapagliflozin 10 mg in Diabetes Mellitus, Type 2, Hyperglycemia and Insulin Resistance, sponsored by Yonsei University. Not yet recruiting at 1 site in South Korea. Open to participants aged 19 Years to 75 Years. Per ClinicalTrials.gov, last updated 2025-08-07.

Sponsored by Yonsei University · Phase 4, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
100
Allocation
Randomized
Ages
19 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 198 studies testing sitagliptin in Diabetes Mellitus, Type 2 — 3 open to participants now, 5 under way, none of them phase 3. sitagliptin · Diabetes Mellitus, Type 2.

Planned enrollment
101st of 197
100 · median 102
Started
2025
with 1 other
Phase 4
68 of 198
3 open now
Registered
197th of 198
by date

Among the 198 studies testing sitagliptin in Diabetes Mellitus, Type 2, this one is the 101st largest by planned enrollment of the 197 interventional ones that give a count, is one of 2 that started in 2025, is one of 68 in phase 4, and was the 197th registered.

Diabetes Mellitus, Type 2

10,403 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,413 are open to participants now.

Browse Diabetes Mellitus, Type 2 studies →

Open to participants now

3 of the 198 studies testing sitagliptin in Diabetes Mellitus, Type 2 are open now, in 3 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

About sitagliptin

sitagliptin: first FDA approval 2006 (JANUVIA), first EMA approval 2007. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 882 Diabetes Mellitus, Type 2 studies recruiting now, 372 (42%) set no upper age limit and 384 (44%) stop at 75 or younger; 52 take children under 18; 202 take healthy volunteers.

This study: 19 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 198 studies testing sitagliptin in Diabetes Mellitus, Type 2, or all of them as a file.
02

Study summary

This clinical trial investigates the effects of adding different diabetes medications to patients with type 2 diabetes who are currently being treated with DPP4 inhibitors. The study evaluates three treatment strategies: SGLT2 inhibitor monotherapy, TZD monotherapy, and a combination of both SGLT2 inhibitor and TZD. Participants will be randomly assigned to one of four groups, including a control group continuing DPP4 inhibitor alone.

The primary objective is to assess changes in blood sugar control, specifically HbA1c levels, after 12 and 24 weeks of treatment. Secondary outcomes include changes in fasting and postprandial glucose, insulin, C-peptide, lipid profiles (total cholesterol, triglycerides, HDL-C, LDL-C), body composition (muscle mass, visceral fat, subcutaneous fat), and insulin resistance indicators such as HOMA-IR, HOMA-beta, and Insulinogenic Index.

Eligible participants are adults aged 19 to 75 years with type 2 diabetes who have been on stable doses of DPP4 inhibitors, with or without metformin or sulfonylurea, for at least 8 weeks. Individuals with recent use of SGLT2 inhibitors or TZDs, significant organ dysfunction, or other exclusion criteria will not be enrolled.

The study is open-label and multicenter, conducted at four hospitals in Korea. All medications used in the trial are provided by the sponsor. Participants will receive lifestyle counseling throughout the study period, including guidance on diet and exercise. Safety monitoring will be conducted regularly, and adverse events will be documented and managed according to protocol.

03

Conditions studied

  • Diabetes Mellitus, Type 2
  • Hyperglycemia
  • Insulin Resistance
04

Who can participate

Ages eligible
19 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Adults aged between 19 and 75 years at the time of providing written .
  2. Diagnosed with type 2 diabetes mellitus and having an level between 7.5% and 11.0%.
  3. Receiving DPP4 inhibitor monotherapy or combination therapy with metformin and/or sulfonylurea for at least 8 weeks without dose adjustment.
  4. Provided written informed consent voluntarily after receiving a full explanation of the study.
  5. Considered capable of understanding the study procedures and cooperating throughout the study period until completion.

Exclusion criteria

Exclusion Criteria:

  1. Patients with diabetes other than type 2 diabetes, including type 1 diabetes or gestational diabetes.
  2. Use of TZD or SGLT2 inhibitors within the past 8 weeks, or history of discontinuation due to serious adverse reactions.
  3. Currently receiving four or more antidiabetic medications.
  4. History of diabetic ketoacidosis (with or without coma) or acute/chronic metabolic acidosis within the past 24 weeks.
  5. Known allergy or to the drugs or their components.
  6. Chronic use (more than 14 consecutive days) of oral or parenteral within 8 weeks prior to screening, with ongoing need for dose adjustment.
  7. Genetic disorders such as galactose intolerance, Lapp lactase deficiency, or glucose-galactose malabsorption.
  8. Active or progressive malignant tumors requiring treatment.
  9. History of drug abuse or alcohol dependence within the past 12 weeks.
  10. infection.
  11. Severe infections, perioperative status, or major trauma.
  12. History of heart failure classified as class III or IV within the past 24 weeks.
  13. History of acute cardiovascular events within the past 12 weeks (e.g., unstable angina, myocardial infarction, , stroke, coronary artery bypass grafting, or coronary intervention).
  14. Renal failure or chronic kidney disease with \< 25 mL/min/1.73m² or undergoing dialysis.
  15. Active bladder cancer or history of bladder cancer.
  16. Abnormal liver function defined as serum , AST, or alkaline phosphatase > 5× , or total > 5× ULN.
  17. Pregnant or breastfeeding women.
  18. Participation in another clinical trial or administration of investigational drugs within the past 12 weeks (except for observational or retrospective studies deemed not to affect the safety or efficacy of this trial).
  19. Determined by the investigator to be unsuitable for participation in the study.
Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
100 participants (estimated)

Study arms

  • Experimental
    A

    Sitagliptin 100 mg

    Drug: Sitagliptin 100 mg

  • Experimental
    B

    Sitagliptin 100 mg + Dapagliflozin 10 mg

    Drug: Sitagliptin 100 mg + Dapagliflozin 10 mg

  • Experimental
    C

    Sitagliptin 100 mg + Lobeglitazone 0.5 mg

    Drug: Sitagliptin 100 mg + Dapagliflozin 10 mg

  • Experimental
    D

    Sitagliptin 100 mg + Dapagliflozin 10 mg + Lobeglitazone 0.5 mg

    Drug: Sitagliptin 100 mg + Dapagliflozin 10 mg + Lobeglitazone 0.5 mg

Interventions

  • DrugSitagliptinStudies of SitagliptinSitagliptin pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Sitagliptin 100 mg, taken once daily for 24 weeks.

  • DrugSitagliptin 100 mg + Dapagliflozin 10 mg

    Drug page: SitagliptinStudies of SitagliptinSitagliptin pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Sitagliptin 100 mg + Dapagliflozin 10 mg, taken once daily for 24 weeks.

  • DrugSitagliptin 100 mg + Dapagliflozin 10 mg

    Drug page: SitagliptinStudies of SitagliptinSitagliptin pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Sitagliptin 100 mg + Dapagliflozin 10 mg, taken once daily for 24 weeks.

  • DrugSitagliptin 100 mg + Dapagliflozin 10 mg + Lobeglitazone 0.5 mg

    Drug page: SitagliptinStudies of SitagliptinSitagliptin pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Sitagliptin 100 mg + Dapagliflozin 10 mg + Lobeglitazone 0.5 mg, taken once daily for 24 weeks.

06

What researchers measure

Primary outcomes

  1. change in HbA1c levels

    To assess the change in HbA1c levels at 12 and 24 weeks after administration of the investigational drugs, by comparing pre- and post-treatment values within each group and between groups.

    Time frame: At 12 and 24 weeks after initiation of the investigational drug

07

Study locations

1 site
  • Department of Internal Medicine, Yonsei University College of Medicine, 50-1 Yonsei-ro, Seodaemun-gu, Seoul 03722, Republic of Korea
    Seoul, 03722, South Korea
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Sep 2025; primary completion for Sep 2029, 48 months later.

Of 320 non-industry phase 4 interventional studies under Diabetes Mellitus, Type 2, half reached primary completion within 31 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 49. This study's planned 48 months is above that.

Counting every sponsor, half of 452 studies reached it within 24 months; a quarter within 13 and three quarters within 42.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 31, 2025
First posted
Aug 7, 2025
StartEst.
Sep 2025
Primary completionEst.
Sep 1, 2029
CompletionEst.
Aug 31, 2030
Last update
Aug 7, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 7, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07108985
Lead sponsor
Yonsei University
Responsible party
Sponsor
First posted
Aug 7, 2025
Start date
Sep 2025 (estimated)
Primary completion
Sep 1, 2029 (estimated)
Completion
Aug 31, 2030 (estimated)
Last update
Aug 7, 2025

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Jul 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Sitagliptin

Start the discussion